Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
Authors:
Open Access
- 16 June 2023
- journal article
- research article
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 24 (1) , 2223388
Abstract
Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 inhibitor) in colorectal cancer (CRC), however single agent therapeutics are often limited by the development of resistance. We compared the anti-proliferative effects of the combination of Gedatolisib and Palbociclib and Gedatolisib and PD0325901 in five CRC cell lines with varying mutational background and tested their combinations on total and phosphoprotein levels of signaling pathway proteins. The combination of Palbociclib and Gedatolisib was superior to the combination of Palbociclib and PD0325901. The combination of Palbociclib and Gedatolisib had synergistic anti-proliferative effects in all cell lines tested [CI range: 0.11-0.69] and resulted in the suppression of S6rp (S240/244), without AKT reactivation. The combination of Palbociclib and Gedatolisib increased BAX and Bcl-2 levels in PIK3CA mutated cell lines. The combination of Palbociclib and Gedatolisib caused MAPK/ERK reactivation, as seen by an increase in expression of total EGFR, regardless of the mutational status of the cells. This study shows that the combination of Palbociclib and Gedatolisib has synergistic anti-proliferative effects in both wild-type and mutated CRC cell lines. Separately, the phosphorylation of S6rp may be a promising biomarker of responsiveness to this combination.Keywords
All Related Versions
Funding Information
- North East Cancer Research and Education Trust (NECRET) and St. Luke’s Institute for Cancer Research
This publication has 52 references indexed in Scilit:
- Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular studyAnnals of Oncology, 2012
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends in Biochemical Sciences, 2011
- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS SignalingCancer Research, 2010
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal AntibodiesCancer Research, 2009
- Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrestBiochemical and Biophysical Research Communications, 2009
- Stress and IGF-I Differentially Control Cell Fate through Mammalian Target of Rapamycin (mTOR) and Retinoblastoma Protein (pRB)Journal of Biological Chemistry, 2008
- Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disordersLaboratory Investigation, 2007
- mTOR, translational control and human diseaseSeminars in Cell & Developmental Biology, 2005
- Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion frontOncogene, 2001
- Ribosomal S6 Kinase Signaling and the Control of TranslationExperimental Cell Research, 1999